Company news

Shuttle Pharmaceuticals Holdings, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

January 7, 2024

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

December 10, 2023

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

November 13, 2023

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

October 30, 2023

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

September 24, 2023

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

September 10, 2023

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

August 14, 2023

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

August 2, 2023

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

May 25, 2023

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

March 21, 2023

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

March 14, 2023

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

March 8, 2023

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

February 22, 2023

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023

January 16, 2023

Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants

January 11, 2023

Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update

November 14, 2022

Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study

November 2, 2022

Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors

October 31, 2022

Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine

September 19, 2022

Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment

September 14, 2022

Shuttle Pharmaceuticals Announces Closing of Initial Public Offering

September 5, 2022

Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH"

August 30, 2022

← Newer news releases

Decks

The 5 newest of 11 decks. Every deck is listed under its year.